Apellis Pharmaceuticals Analyst Ratings
Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $43
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $39
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Apellis Pharmaceuticals Analyst Ratings
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities
Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan
Apellis Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
Apellis Pharmaceuticals Analyst Ratings